[106 Pages Report] The global point of care molecular diagnostics market was valued at USD 632.5 Million in 2017 and is projected to reach USD 1,440.2 Million in 2023, at a CAGR of 14.7%. The scope of the study includes POC molecular diagnostics analyzers and assays that enable healthcare professionals in the detection of diseases through molecular technologies in point-of-care settings. The base year considered for the study is 2017, and the forecast for the market size is provided for the period between 2018 and 2023.
The key players in the global Point of care molecular diagnostics market are, Roche Diagnostics (Switzerland), Biomerieux (France), Danaher (US), Abbott Laboratories (US), Quidel (US) and Meridian Bioscience (US).
https://www.marketsandmarkets.com/Market-Reports/point-of-care-molecular-diagnostic-market-143524127.html
Objectives of the Study
• To define, describe, and segment the global Point of care molecular diagnostics market by product & service, technology, application, end user, and region
• To provide detailed information about factors influencing market growth (drivers, restraints, and opportunities)
• To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the global POC molecular diagnostics market
• To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
• To forecast the size of the market segments with respect to four major regional segments, namely, North America, Europe, Asia Pacific (APAC), and the Rest of the World (RoW)
• To profile the key players in the market and comprehensively analyze their market positions and core competencies
• To track and analyze competitive developments such as acquisitions, product launches and approvals, expansions, and other developments in the POC molecular diagnostics market
Based on the applications, the market is segmented into respiratory diseases, hospital-acquired infections (HAIs), sexually transmitted diseases (STDs), oncology, hepatitis, and other applications (meningococcal meningitis, malaria, Herpes Simplex Virus, Ebola, Zika virus). The respiratory application segment is expected account for the largest share of the global POC molecular diagnostics market in 2018. This large share of this segment can be attributed to the rising prevalence of influenza A & B and increasing research investments by key players for other respiratory disease such as Strep A and TB. In addition to this, most of the FDA approved RT-PCR POC molecular diagnostics are focused on influenza disease.
Get PDF brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=143524127
The POC molecular diagnostics market is broadly segmented into instruments, assays & kits, and services & software based on the basis of product & service. Assays & kits segment is expected to account for the largest share of the global POC molecular diagnostics market and expected to register the highest CAGR during the forecast period. POC molecular diagnostic assays and kits are specially designed for points of care such as hospital critical care units, physician offices, outpatient clinics, and community health posts. POC molecular diagnostics assays and kits enable the early diagnosis of respiratory tract infections, women’s health and sexual health conditions and among others.